ES2548386T3 - Formas cristalinas de saxagliptina - Google Patents
Formas cristalinas de saxagliptina Download PDFInfo
- Publication number
- ES2548386T3 ES2548386T3 ES10713211.0T ES10713211T ES2548386T3 ES 2548386 T3 ES2548386 T3 ES 2548386T3 ES 10713211 T ES10713211 T ES 10713211T ES 2548386 T3 ES2548386 T3 ES 2548386T3
- Authority
- ES
- Spain
- Prior art keywords
- saxagliptin
- crystalline forms
- crystalline
- water content
- relative humidity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
Formas cristalinas anhidras de monoclorhidrato de saxagliptina que tienen un contenido en agua de no más del 1,5% p/p.
Description
E10713211
25-09-2015
Tabla 1: Ángulos 2-theta, valores de d e intensidades relativas de la forma I-S
- Ángulo [º 2-Theta]
- Valor de d [Angstrom] Int. rel [%]
- 6,72
- 13,145 100
- 10,30
- 8,591 4
- 11,68
- 7,577 3
- 13,52
- 6,548 12
- 14,63
- 6,054 46
- 15,15
- 5,846 36
- 16,60
- 5,340 32
- 17,91
- 4,952 53
- 18,80
- 4,721 7
- 19,19
- 4,624 7
- 20,33
- 4,368 4
- 21,46
- 4,141 4
- 22,17
- 4,010 5
- 24,50
- 3,634 17
- 27,01
- 3,301 6
- 28,16
- 3,169 12
- 29,78
- 3,001 9
- 30,59
- 2,922 9
- 31,33
- 2,855 9
- 31,87
- 2,808 3
- 34,27
- 2,616 4
- 36,25
- 2,478 5
La forma cristalina I-S de monoclorhidrato de saxagliptina obtenida anteriormente tiene un espectro de IR de reflectancia total atenuada con bandas de absorción a 2907, 2853, 1637, 1589, 1462, 1391, 1318, 1045, 1014 y 775 5 cm -1 (± 2 cm-1; figura 2)
Se sometió la forma cristalina I-S obtenida a análisis térmico diferencial. Tal como puede observarse en la figura 3 (curva inferior), la forma cristalina I-S no muestra endoterma de deshidratación significativa sino sólo un pico a 241ºC (Tcomienzo de 230ºC; velocidad de calentamiento de 10ºC/minuto, cápsula perforada). Se determinó el cloro iónico como del 10,7% (en teoría el 10,08%).
10 Se determinó el contenido en agua de la forma cristalina I-S obtenida como del 1,2% p/p usando un aparato de Karl
11
E10713211
25-09-2015
- Ángulo [º 2-Theta]
- Valor de d [Angstrom] Int. rel. [%]
- 4,08
- 21,652 100
- 4,72
- 18,738 15
- 6,25
- 14,143 29
- 13,91
- 6,368 6
- 14,51
- 6,104 23
- 14,89
- 5,948 5
- 15,64
- 5,667 39
- 16,69
- 5,312 22
- 18,55
- 4,784 29
- 19,37
- 4,582 10
- 19,8
- 4,484 6
Se sometió la forma cristalina IV-S obtenida a análisis termogravimétrico. Tal como puede observarse en la figura 11, la forma cristalina IV-S muestra una pérdida de masa de aproximadamente el 12,8% desde el comienzo hasta 100ºC. Esta pérdida de masa corresponde a 2,86 moles de agua.
5 El análisis de sorción de humedad muestra un contenido en agua del 13,1% a una humedad relativa del 40% a 25ºC correspondiente a 2,94 moles de agua. El análisis de sorción de humedad muestra un contenido en agua del 12,8% correspondiente a una humedad relativa del 2,86% a una humedad relativa del 0%. El proceso es reversible.
A una humedad relativa de más del 40%, la forma IV-S se transforma de manera irreversible en la forma de dihidrato H2-1 conocida.
10
15
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16791809P | 2009-04-09 | 2009-04-09 | |
EP09157723 | 2009-04-09 | ||
EP09157723 | 2009-04-09 | ||
US167918P | 2009-04-09 | ||
EP09175259 | 2009-11-06 | ||
EP09175259 | 2009-11-06 | ||
PCT/EP2010/054692 WO2010115974A1 (en) | 2009-04-09 | 2010-04-09 | Crystal forms of saxagliptin |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2548386T3 true ES2548386T3 (es) | 2015-10-16 |
Family
ID=42935672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10713211.0T Active ES2548386T3 (es) | 2009-04-09 | 2010-04-09 | Formas cristalinas de saxagliptina |
Country Status (12)
Country | Link |
---|---|
US (2) | US20120088808A1 (es) |
EP (1) | EP2417107B1 (es) |
JP (2) | JP6088245B2 (es) |
KR (1) | KR20120006047A (es) |
CN (2) | CN104016902B (es) |
AU (1) | AU2010233718B2 (es) |
BR (1) | BRPI1006547A2 (es) |
CA (1) | CA2757934C (es) |
ES (1) | ES2548386T3 (es) |
PL (1) | PL2417107T3 (es) |
RU (1) | RU2539590C2 (es) |
WO (1) | WO2010115974A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0487425A (ja) * | 1990-07-31 | 1992-03-19 | Fujitsu Ltd | 回線切り替え装置 |
ES2548386T3 (es) * | 2009-04-09 | 2015-10-16 | Sandoz Ag | Formas cristalinas de saxagliptina |
ES2546866T3 (es) | 2009-12-16 | 2015-09-29 | Hetero Research Foundation | Polimorfos de darunavir |
CA2799762C (en) | 2010-05-20 | 2018-03-06 | Hetero Research Foundation | Crystalline hydrochloride salt of darunavir |
EP2608788A1 (en) | 2010-10-04 | 2013-07-03 | Assia Chemical Industries Ltd. | Polymorphs of saxagliptin hydrochloride and processes for preparing them |
WO2013036213A1 (en) | 2011-09-07 | 2013-03-14 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dpp-iv inhibitor formulations |
EP2578208B1 (en) | 2011-10-06 | 2014-05-21 | Sanovel Ilac Sanayi ve Ticaret A.S. | DPP-IV inhibitor solid dosage formulations |
WO2013136343A1 (en) | 2012-03-12 | 2013-09-19 | Mylan Laboratories Ltd. | Amorphous saxagliptin hydrochloride |
EP2841419A1 (en) * | 2012-04-25 | 2015-03-04 | Enantia, S.L. | Crystalline forms of saxagliptin |
AU2013264925B2 (en) | 2012-05-24 | 2017-08-17 | Apotex Inc. | Salts of saxagliptin with organic acids |
EP2867206A2 (en) | 2012-07-02 | 2015-05-06 | Ranbaxy Laboratories Limited | Saxagliptin salts |
WO2015067223A1 (en) | 2013-11-06 | 2015-05-14 | Zentiva, K., S. | L-tartrate salt of (1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl) acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile and process for preparation thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6032616B2 (ja) * | 1976-08-24 | 1985-07-29 | アレクサンダ− ガラツト | 高い貯蔵安定性の無水アセチルサリチル酸ナトリウム |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US7420079B2 (en) * | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
US6995183B2 (en) * | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
TWI354569B (en) * | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
AU2005264065A1 (en) * | 2004-07-16 | 2006-01-26 | Warner-Lambert Company Llc | Hair growth promoting agents |
US20060035954A1 (en) * | 2004-08-11 | 2006-02-16 | Sharma Padam N | Ammonolysis process for the preparation of intermediates for DPP IV inhibitors |
PE20090696A1 (es) * | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
ES2548386T3 (es) * | 2009-04-09 | 2015-10-16 | Sandoz Ag | Formas cristalinas de saxagliptina |
-
2010
- 2010-04-09 ES ES10713211.0T patent/ES2548386T3/es active Active
- 2010-04-09 CN CN201410283458.2A patent/CN104016902B/zh not_active Expired - Fee Related
- 2010-04-09 JP JP2012504028A patent/JP6088245B2/ja not_active Expired - Fee Related
- 2010-04-09 US US13/262,652 patent/US20120088808A1/en not_active Abandoned
- 2010-04-09 AU AU2010233718A patent/AU2010233718B2/en not_active Ceased
- 2010-04-09 BR BRPI1006547A patent/BRPI1006547A2/pt not_active Application Discontinuation
- 2010-04-09 CA CA2757934A patent/CA2757934C/en not_active Expired - Fee Related
- 2010-04-09 WO PCT/EP2010/054692 patent/WO2010115974A1/en active Application Filing
- 2010-04-09 PL PL10713211T patent/PL2417107T3/pl unknown
- 2010-04-09 EP EP10713211.0A patent/EP2417107B1/en not_active Not-in-force
- 2010-04-09 KR KR1020117026595A patent/KR20120006047A/ko active IP Right Grant
- 2010-04-09 CN CN201080025360.7A patent/CN102459170B/zh not_active Expired - Fee Related
- 2010-04-09 RU RU2011145054/04A patent/RU2539590C2/ru not_active IP Right Cessation
-
2013
- 2013-10-02 US US14/044,204 patent/US9260389B2/en active Active
-
2015
- 2015-07-16 JP JP2015141890A patent/JP2016006063A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2539590C2 (ru) | 2015-01-20 |
CA2757934C (en) | 2017-12-19 |
BRPI1006547A2 (pt) | 2016-10-18 |
JP6088245B2 (ja) | 2017-03-01 |
PL2417107T3 (pl) | 2016-02-29 |
CN104016902A (zh) | 2014-09-03 |
WO2010115974A1 (en) | 2010-10-14 |
RU2011145054A (ru) | 2013-05-20 |
US9260389B2 (en) | 2016-02-16 |
US20120088808A1 (en) | 2012-04-12 |
CN102459170B (zh) | 2014-07-23 |
KR20120006047A (ko) | 2012-01-17 |
AU2010233718B2 (en) | 2015-11-05 |
EP2417107A1 (en) | 2012-02-15 |
JP2016006063A (ja) | 2016-01-14 |
CN102459170A (zh) | 2012-05-16 |
AU2010233718A1 (en) | 2011-10-27 |
JP2012523395A (ja) | 2012-10-04 |
CN104016902B (zh) | 2017-10-20 |
CA2757934A1 (en) | 2010-10-14 |
EP2417107B1 (en) | 2015-08-26 |
US20140200252A1 (en) | 2014-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2548386T3 (es) | Formas cristalinas de saxagliptina | |
PH12015501108A1 (en) | Treatment of pulmonary disease | |
CL2015002145A1 (es) | Preparación, usos y formas sólidas de ácido obeticólico (divisional de solicitud n° 3475-2014) | |
CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
PE20142350A1 (es) | Composicion para el tratamiento de aguas y metodos de uso | |
CL2014001858A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer. | |
SI2931713T1 (sl) | Derivati kloro-pirazin karboksamida uporabni za zdravljenje bolezni favoriziranih z nezadostno hidracijo sluznice | |
PE20140616A1 (es) | Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecan (folfiri) | |
CL2011000696A1 (es) | Particulas inhalables que comprenden una forma anhidra amorfa de tiotropio con un agente estabilizante que es lactosa; composicion farmaceutica; procedimiento para prepararlas que incluye secado por atomizacion; y su uso en asma y epoc | |
CL2010000471A1 (es) | Metodo para preparar pasteles de cereales aireados que comprende introducir un cereal integral en un horno giratorio, cocer el cereal con vapor y agua, secar el cereal hasta humedad entre 10 y 17% y airear el cereal integral; un pastel de cereal integral. | |
CL2015001869A1 (es) | Composición inyectable acuosa de diclofenaco en una solucion de eter monoetilico de dietilenglicol y agua; metodo de preparacion; y uso en el tratamiento o prevencion del dolor y/o condiciones inflamatorias como dolor de cabeza, dolor de garganta, entre otras. | |
MX2020005738A (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
AR090940A1 (es) | Procedimiento para la fabricacion de una forma farmaceutica que comprende nifedipino y candesartan cilexetilo | |
CN204292160U (zh) | 蔬菜烘干机 | |
EA201300910A1 (ru) | Фармацевтическая композиция с содержанием селенита или содержащие селенит соединения для лечения дисплазий или карцином шейки матки | |
CA2866819C (en) | Method for treating inflammation | |
IN2013MU01286A (es) | ||
IL218392A (en) | Pharmaceutical shelf, use of it for the treatment of sham, commercial package containing it and use of fat derivatives for the preparation of a drug for the treatment of mucositis | |
WO2015036972A3 (en) | Selective dopamine d4 receptor agonists for treatment of working memory deficits | |
CN204154638U (zh) | 试验用小型拉布装置 | |
CL2009001005A1 (es) | Compuestos derivados de butirato de trimetilamonio, inhibidores de cpt2; proceso de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de enfermedades tales como hiperglucemia, diabetes, hipertension, entre otras patologias. | |
AR052209A1 (es) | Un proceso tecnologico de deshidratacion para formar geles laminados de pure de tomate | |
PH12015502560B1 (en) | Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease | |
CO7240380A2 (es) | Composiciones líquidas orales pediátricas que contienen nepadutant | |
Miceli et al. | Correction to “First Principles Study of the LiNH2/Li2NH Transformation” |